Proteolix: A “Me-Too” Success
以生物技术公司Proteolix为例，分析其采用风险较低的“我也是”药物开发策略如何取得成功，对研究生物技术企业战略的学者有参考价值。
In an industry rife with failures, Proteolix, a biotechnology company, was a rare success. The Proteolix case provides a compelling example of a biotech company that has chosen a “me-too” strategy, a less risky strategy than the strategy of discovering a drug for a novel target. However, even me-too drug strategies in the biotech industry face an uphill battle.